Organophosphate poisoning is common in developing countries. The morbidity and mortality with organophosphate poisoning is relatively high despite the use of atropine as specific antidotal therapy and oximes to reactivate acetylcholinesterase. Several adjunct and alternative therapies have been explored in animal and human studies. We reviewed the literature to ascertain if there was evidence of benefit of such therapies. Adjunct and alternative therapies included treatments to reduce poison absorption by topical application of creams, enhance toxin elimination by haemoperfusion or bioremediation and neutralise the poison by scavenging free organophosphate with cholinesterase-rich human plasma. In addition, magnesium, clonidine, diazepam, N-acetyl cysteine and adenosine receptor agonists have also been used to counteract poison effects. Detailed assessment was limited by the paucity of trials on adjunct/alternative therapies. The limited evidence from the review process suggested potential benefit from the use of human plasma infusion, early initiation of haemoperfusion and intravenous magnesium, in addition to standard therapy with atropine and pralidoxime. There appeared to be no additional benefit with alkalinisation or use of glycopyrrolate instead of atropine in human trials. Diazepam administration has been advocated by military authorities if symptoms developed following exposure to organophosphate. Bioremediation, clonidine, N-acetyl cysteine and adenosine receptor agonists have been evaluated only in animal models. The impact of adjunct and alternate therapies on outcomes in human poisoning needs to be further explored before implementation as standard treatment.
Although organophosphate poisoning (OP) is frequent in developing countries 1 , exposure to insecticides is not uncommon in developed nations 2 . This, combined with threats and acts of bioterrorism 3 , has resulted in the search for effective treatments that would reverse or mitigate the effects of poisoning 4 and hasten recovery. Although oximes have been widely studied and shown to have protective effects in experimental OP poisoning, the results in human trials have been less promising 5 . Meta-analyses have not been able to establish 5, 6 . The lack of oxime effect was postulated to be due the type of organophosphate compound (dimethyl vs. diethyl), the (lag) time to administer the antidote, (inadequate) oxime dosage and oxime toxicity 5, 7 . There is, however, recent evidence for a therapeutic poisoned patients presenting very early (within 2.5 hours) to hospital 8 . Nonetheless, only 15% present to hospital within six hours of poisoning in other centres 7 . Delayed presentations, potential harmful effect of oximes as well as lack of evidence intoxications have prompted the search for other therapies. This review evaluates the role of adjunct treatments and alternatives to oxime therapy in improving outcomes in OP poisoning.
METHODS
We performed a literature search (1966 to September 2007) using PubMed ® with the search terms "organophosphate or organophosphorus or pesticide or insecticide" and "poison or poisoning" (MESH) and "treatment or therapy" (MESH).
search was used for further exploratory search. This included "plasma", "plasma-exchange", "magnesium", "dialysis", "diazepam", "haemoperfusion", "adenosine receptor agonists", "clonidine", "N-acetyl cysteine", "glycopyrrolate" and "alkalinisation". We also reviewed our personal controlled trials and reviews on OP poisoning, to identify additional articles pertaining to therapy in OP poisoning. The focus was to provide a general review of adjunct and alternative therapies in organophosphate poisoning in animals and humans.
for the implementation of any of these therapies in human poisoning. Although decontamination in ingestional OP poisoning and diazepam in deliberate OP exposure (military/civilian situations) may be considered 'standard' adjunct therapy, these therapies were discussed in brief to provide an overall view of all adjunct therapy. Given the current extensive literature on oxime therapy, this was not further addressed.
Outcomes evaluated included mortality, need for mechanical ventilation and incidence of intermediate syndrome. Intermediate syndrome respiratory distress occurring 24 to 96 hours after OP ingestion with or without the need for mechanical ventilation 9 . Studies on each adjunct/alternative therapy were categorised as experimental/animal studies or human/clinical studies. Studies of adjunct treatments in humans were evaluated in terms of methodology and study quality. A formal assessment of study quality was performed using a quality score 10 assessed composite aspects of study quality (10 aspects in total, each with scores 0 or 1). In addition, we used the Oxford Centre for Evidence-Based Medicine Levels of Evidence (Appendix 2) for therapy (whether a treatment 11 , to categorise the level and grade of evidence for each adjunct therapy evaluated in human organophosphate poisoning. Two authors graded the evidence (JVP, JLM). Where there were differences in opinion a consensus was reached. 
RESULTS
by literature search, 603 pertained to treatment in OP poisoning. Treatments evaluated in humans included magnesium, haemoperfusion, alkalinisation, plasma and glycopyrrolate. In addition, N-acetyl cysteine (NAC), diazepam, clonidine and adenosine receptor agonists were explored in animal models. The seven studies on adjunct/alternate therapies in human poisoning included three studies on haemoperfusion [12] [13] [14] , one systematic review on alkalinisation 15 and one study each on magnesium 16 , plasma 9 and glycopyrrolate 17 . Five studies that had a control arm (Table 1) were of low to moderate quality (scores 3 to 6, Appendix 1). The physiological basis of these therapies, as available from animal and experimental data, were reviewed and presented. For the purpose of description, therapies were broadly categorised as treatments aimed at: 1) reducing absorption; 2) neutralising toxin; 3) counteracting effects of OP; and 4) enhancing elimination.
DISCUSSION

Reduce OP absorption
A vital aspect of management is to reduce poison load. This can be achieved by skin and gastric decontamination, considered standard care for poison exposure. Skin decontamination is performed by removing contaminated clothing and by washing the skin with soap and water. Topical creams and lotions have some promise in experimental OP poisoning 18 .
Gastric decontamination is performed after ensuring airway protection. Although there are no studies on gastric decontamination in human OP poisoning, toxin clearance is maximal if gastric decontamination is performed within one to two hours of intoxication 19 . However, the hazards of gastric lavage need to be kept in mind especially in countries with limited resources for performing the procedure safely 20 .
Recommendations: The American Academy of Clinical Toxicology and the European Association of Poisons Centres and clinical toxicologists position paper suggests that "gastric lavage should not be employed routinely, if ever, in the management of poisoned patients" (Grade C, Level 4 evidence) 21 .
Neutralise toxin Bioscavenger therapy
In addition to oximes, which neutralise the toxin by cleaving covalently bound OP from the OP-acetylcholinesterase (AChE) conjugate, bioscavenger therapy has been recently popularised as a potential treatment to scavenge and neutralise free OP.
Bioscavenger therapy involves the use of enzymes such as cholinesterases (ChEs) as single "pretreatment" agents to sequester highly toxic OP compounds before they reach their physiological targets. This novel approach involves use of ChEs such as beta-esterases as "anti-OP agents" rather than viewing the OP as an "anti-cholinesterase" 22 .
Bioscavengers in OP poisoning can be categorised as: a) OP hydrolases and anhydrases-enzymes catalytically hydrolysing and inactivating OP compounds; b) cholinesterases and related enzymes-those stoichiometrically binding and neutralising OP; and c) pseudocatalytic-a combination of ChE and oxime pre-treatment 22 .
The prerequisites of a good bioscavenger include prolonged circulatory residence time and the absence of anti-enzyme antibodies following repeated injections 22 . Initial studies on daily equine butyrylcholinesterase (BChE) administration into rabbits and rats resulted in anti-enzyme antibody production and reduced enzyme activity 22 . Subsequent studies demonstrated that macaques of the same species resulted in prolonged residence time compared to heterologous BChE (225±19 [n=4] vs. 33.7±2.9 [n=3] hours, P=0.002) and lack of antibody production 23 .
advantages for "prophylactic" use 22, 24 . It has a rapid and broad range of action against various toxic OPs including soman, sarin and tabun, is readily absorbed from injection sites and has a long circulatory retention time. Recent pharmacokinetic studies of human BChE in mice demonstrated that a single dose of BChE was able to maintain therapeutic concentrations for at least four days 24 . Further the lyophilised form had a shelf life of >two years at 4 to 45°C. Given its human source, the potential for adverse immunological responses would also be limited. Safety and toxicity studies again indicate that human BChE at 30 times the therapeutic dose was devoid of tissue toxicity in mice. It has been suggested that 200 mg of human BChE could protect humans from exposure of 2 to 5 × LD 50 of nerve agents 22, 24 . Although these factors favour the development of BChE as a bioscavenger for human OP 'exposure', more recent literature suggests that a large quantity of BChE would be required for neutralisation and inactivation 25 .
There are no human trials with BChE. However until phase III trials are conducted, an alternative approach to evaluate bioscavenger therapy would be to use ChE-rich human plasma. In a preliminary study of 33 OP poisoned patients 9 , 20 patients received atropine and pralidoxime and nine in addition received two bags of plasma daily from day two until they no longer required atropine. Two patients received plasma after onset of intermediate syndrome, one only atropine and the other atropine and plasma. The authors observed that while intermediate syndrome occurred in 28.8% (6/21) of patients receiving atropine and pralidoxime, none developed intermediate syndrome if plasma was co-administered (0/9). The mortality rate was 18.2% (4/22) in patients not receiving plasma. Although no deaths occurred in patients (n=9) receiving plasma prior to onset of intermediate syndrome, the two patients who received plasma following onset of intermediate syndrome died (Table 1 ). It was suggested that in these two patients who died, BChE might not have been effective once neuromuscular involvement developed. BChE levels in the plasma were 4069.5±565.1 IU/l. Every two bags of plasma increased BChE levels by 461.7±142.1 IU/l 9 . In a case report, the same authors reported clinical improvement with plasmapheresis using fresh frozen plasma 26 . It is unclear if BChE is the 'secret' ingredient 27 as a recent study suggested that albumin could serve to scavenge OP molecules and reduce OP available for reaction with AChE 28 .
Recommendation: Although the above study on plasma was underpowered and methodological weaknesses limit interpretation (Grade C, Level 4 investigation of BChE and albumin, as 'bioscavengers' in OP poisoning.
Counteract OP effects Anticholinergics
Although atropine is administered to counteract the haemodynamic effects of OP and clear pulmonary secretions, there is experimental evidence 29 . The recommended until atropinisation 30 . Despite atropine being the antidote of choice, adverse reactions may preclude its use in some patients. Adverse side-effects may lead to clinical toxicity even at therapeutic doses, or manifest rarely as anaphylaxis 31 . The potential advantage of glycopyrrolate of lack of penetration into the blood brain barrier may favour its use over atropine in patients manifesting atropine toxicity 17 .
In a recent case report of an OP poisoned patient, profuse bronchorrhoea that persisted despite clinical signs of 'adequate' atropinisation, resolved with glycopyrrolate 32 . In the only study comparing atropine (n=22) with glycopyrrolate (n=17), although there was a trend towards lesser respiratory complications with glycopyrrolate, other outcomes were similar 17 .
Recommendation: There is currently inadequate evidence for the preferential use of glycopyrrolate over atropine in OP poisoning (Grade C, Level 4 evidence). The cost of glycopyrrolate also limits routine use (0.2 mg of glycopyrrolate is about twice the cost of 0.6 mg of atropine).
Magnesium
The physiological basis for magnesium comes from observations that magnesium reversed the decrement in the force of contraction and compound muscle action potential in rat diaphragm 33 . A similar effect has been observed in human poisoning 34 . Magnesium might also offer protection by reducing the stimulatory effect of acetylcholine on the muscle 35 .
Intravenous magnesium, in addition, has important electrophysiological effects 36, 37 on the heart that are independent of initial plasma concentrations 38 . Its most notable effect is the ability to prevent episodes of drug-induced torsades de pointes (TDP) 39 . Long QTc with TDP risk is not only seen with congenital syndromes and drugs such as anti-arrhythmic agents but also in cocaine and OP poisoning 40, 41 .
Several studies have reported QTc prolongation, ventricular tachycardia and other cardiac manifestations that might contribute to death in OP poisoning [42] [43] [44] . In the developed world where OP poisoning is relatively uncommon, cardiac arrest may be the rare presenting manifestation of poisoning and the appropriate diagnosis may be missed 45 .
The mechanism of cardiac toxicity is unclear. Many factors probably predispose to cardiac manifestations including sympathetic/parasympathetic overactivity, hypoxaemia, acidosis, electrolyte derangement and direct toxic effects of the OP on the myocardium 46 . There is some evidence from animal experiments that magnesium improves survival by improving haemodynamics in paraoxon treated mini-pigs 47 .
The earliest report of magnesium in human OP poisoning was the successful treatment of a patient with TDP using magnesium and atropine 48 .
In a recent pilot study using systematic sampling 16 , every fourth eligible patient was chosen to receive 24 hours after admission. The mean daily oxime and atropine requirement was similar in both groups. The mortality rate (14.7% vs. 0%) and hospitalisation days (5.0±0.82 vs 2.9±0.66 days) were P <0.01) in patients receiving magnesium. Although the authors concluded that limited by small sample size (n=11 treated with magnesium), lack of blinding, the sequential mode of randomisation and no placebo administration in the control arm. Further, it was not clear from the study if cardiac arrhythmia contributed to death in the control group. The dose of magnesium used for OP poisoning was much smaller than doses used for pre-eclampsia of 4 grams bolus magnesium sulphate followed by 1 gram infusion 49 .
Recommendations: Despite evidence from animal experiments and physiological basis for magnesium recommend routine administration except in patients who manifest arrhythmias (Grade C, Level 4 evidence).
Diazepam
There is evidence that overstimulation of the central receptors by OP compounds may contribute to early death in OP poisoning. In experimental animals, OP compounds evoke excitatory electroencephalographic and physiologic changes in the respiratory control regions of the brain and peripheral feedback systems 50, 51 . In addition, there is suggestion that OP compounds increase phrenic nerve output followed by sudden cessation of activity, potentially from focal respiratory centre seizures 51, 52 . These observations favoured the evaluation of diazepam in OP poisoning.
In early experiments, pre-treatment with centrally acting agents atropine or diazepam dramatically increased 24-hour survival in Wistar rats administered 25 mg/kg of dichlorvos subcutaneously 29 . In contrast, none of the peripherally acting agents (ipratropium or glycopyrrolate) by itself impacted survival (0% survival at 10 minutes). However, when either of these peripherally acting agents were combined with diazepam, survival with both ipratropium and glycopyrrolate improved to 88% at 24 hours 29 . In another study, 23/24 animals treated with injected or nebulised atropine, or diphenhydramine survived 24 hours, whilst mortality was >88% at 10 minutes for saline controls, glycopyrrolate and ipratropium treated animals 53 . Morphine and diazepam in a recent study again had similar protective effects 54 . These observations argue that early death in OP poisoning is at least in part centrally mediated.
NATO doctrine mandates that each soldier carries three doses each of atropine (2 mg each) and pralidoxime (600 mg each) in addition to 10 mg of diazepam that are to be administered intramuscularly post-exposure if symptoms develop 55 . Improvements in respiratory function and conscious level have also been reported in humans administered diazepam rapidly prior to intubation 56 .
Recommendation: Diazepam is considered standard therapy for deliberate OP exposure (Grade D, Level 5 evidence). There is no evidence to support routine use in ingestional OP poisoning unless used for the treatment of seizures.
Adenosine receptor agonists
Adenosine, a naturally occurring neurotransmitter modulator in the central and peripheral nervous system, acts on the A1 pre-synaptic adenosine receptors to reduce calcium entry through the voltage-gated P/Q Ca 2+ channels in the pre-synaptic neurone 57, 58 . Since both ACh and glutamate release agonists are postulated to attenuate the build-up of ACh and glutamate in synapses of the neuromuscular junctions, cerebral cortex and brainstem respiratory centres.
In murine soman poisoning, immediate postexposure intramuscular administration of adenosine agonists NECA (5'-N-ethylcarboxamido-adenosine) or CPA (N6-cyclopentyl adenosine), in addition to reducing extracellular brain ACh levels, prevented or postponed chewing, salivation, convulsive activity and respiratory distress and improved 24-hour survival rates 59 . In another study, adenosine agonists reduced mortality from experimental animal models of tabun or sarin intoxication but were ineffective against VX or parathion 60 .
Recommendation: Although the mechanism of action of adenosine agonists is novel, it is still a long way from evaluation in humans.
Clonidine
Several studies have explored the role of clonidine. Pre-administration of clonidine resulted in a dose-related inhibition of soman-induced cardiovascular changes and enhanced the survival time as well of number of animals surviving soman administration 61 . In another study both atropine and clonidine were equally effective at limiting soman-induced lethality and behavioural changes 62 . The protective effects of atropine and clonidine were synergistic 62 with simultaneous administration of both agents completely eliminating lethality and behaviour changes produced by 200 μg/kg of soman. In a subsequent study, although pyridostigmine clonidine and not pyridostigmine was able to inhibit the signs of central toxicity of soman 63 , suggesting a centrally mediated effect of clonidine.
Recommendation: There does not appear to be any work on clonidine in experimental models or humans over the last 15 years. Its hypotensive effects may limit further evaluation in OP poisoning.
N-acetyl cysteine
The increasing evidence that OPs may induce oxidative stress leading to the generation of free radicals and cause alterations in the antioxidant status or reactive oxygen species scavenging enzymes 64 makes treatment with NAC promising. In experimental OP poisoning, mice treated with fenthion were administered NAC either prophylactically or therapeutically and compared with saline or atropine treated mice 65 . NAC, both prophylactically and therapeutically, had a protective effect and improved mortality compared with controls not receiving NAC. The survival rates were however lower than atropine-treated mice. Since OP poisoned patients generally do not manifest hepatotoxicity NAC probably confers stress by decreasing malondialdehyde levels and increasing glutathione, nitrate and nitrite levels.
Recommendation: There does not appear to be strong physiological basis for the use of NAC in OP poisoning. There are no studies on humans.
Enhance elimination
Haemoperfusion Extracorporeal removal of toxins is established treatment for various intoxications. The method of extracorporeal removal is dependent on the volume of distribution (V d ), protein binding, as well as solubility of the compound in water. Haemodialysis is suited for water-soluble, dialysable substances such as ethylene glycol while plasmapheresis is recommended for protein bound drugs 66 . Haemoperfusion is effective for substances with a small V d and a molecular weight of less than 10,000 Da 12 . Although the small molecular weight of some OPs (Malathion 330, Dichlorvos 221) makes haemoperfusion an attractive means of poison removal, the large V d 12 . Several animal experiments have evaluated the role of haemoperfusion in OP poisoning. In an early study, haemoperfusion with activated charcoal effectively removed methamidophos and reduced the toxin burden. Although 27% of the administered were not protected against lethal doses of the insecticide 67 . In a subsequent study haemoperfusion through Synachrom E-5 in intoxication with nerve agents sarin and the VX type was only found to be partially successful 68 .
The impetus to use haemoperfusion in human OP poisoning came from studies in the 1970s that showed high clearance values of 83.70 ml/min and 87.84 ml/min for demethon-S-methyl sulfoxide and dimethoate respectively using charcoal haemoperfusion 69 . However, the effect of a large V d Chuecos et al 3 . In 10 patients with OP poisoning, plasma insecticide concentrations and cholinesterase activity were measured daily, in addition to two to three biopsies of fat tissue performed at one to two week intervals. The authors noted no change in patient symptoms with haemoperfusion and only <0.1% of total absorbed poison was removed by haemoperfusion. The fat concentration of the insecticide was 20 to 50 times higher than plasma concentrations and this suggested that the high lipid solubility and large V d of the OP compound that might have rendered haemoperfusion ineffective.
In a recent retrospective report, 25 patients with severe OP poisoning treated with haemoperfusion were compared with 27 patients with mild poisoning not receiving haemoperfusion 12 . Seven patients with severe poisoning died, all in the haemoperfusion group. Although AChE levels increased with haemoperfusion, both in survivors and non-survivors, the increment in AChE did not impact survival. The retrospective nature of the study is a limitation.
In a prospective study of 108 patients with severe dichlorvos poisoning, 67 patients received charcoal haemoperfusion and supportive therapy including pralidoxime (1 to 2 grams every six hours) while 41 patients received only supportive treatment including pralidoxime 14 . Haemoperfusion was (7.5% vs. 34.1%, P <0.01), need for mechanical ventilatory support (13.4% vs. 36.6%, P <0.01), duration of intensive care unit stay (P <0.05) and duration of coma (P <0.01). Serum dichlorvos reduced with haemoperfusion. The control arm mortality (34%) was however substantially higher than the 12 to 14% mortality in recent OP literature 70, 71 . The mode of randomisation was also not stated in the article.
The time of provision of haemoperfusion may (5.6±4.8 hours) initiation 14 favouring good outcomes compared with delayed (27±32 hours) initiation of haemoperfusion 12 . Further supportive evidence of a time effect relates to a case report where combined haemodialysis and haemoperfusion initiated within two hours of severe dimethoate poisoning reduced serum dimethoate levels from 3110 ng/ml to undetectable after 18 hours of extracorporeal therapy 72 . Quality of individual trials sub-optimal, lack of benefit on meta-analysis of controlled trials 5, 6 Early presenters, moderate intoxication, high dose pralidoxime effective 8 , late presenters, severe intoxication, no evidencephysicians preference 7
Grade B Level 2b
Bioscavenger therapy
Animal studies with purified BuChE promising 23, 24 Single controlled trial using fresh frozen plasma 9 Clinical benefit seen, methodological weakness limit study, potential for further evaluation
Grade C Level 4
Counteract effect of toxin Anticholinergics Animal studies reduction in mortality 29, 53 One study comparing atropine with glycopyrrolate 17 No evidence for preferential use of glycopyrrolate over atropine Grade C Level 4
Magnesium
Reduced CMAP 33, 34 , reduces stimulatory effect of ACh on NMJ 35 , benefits in animals 47 One controlled trial using 4 gm of magnesium sulphate over 24 hours 16 Significant mortality benefit, reduced hospital stay, methodological weakness limit study, potential for further evaluation
Grade C Level 4
Diazepam Survival benefit in animals 29, 54 No studies in humans NATO mandates diazepam use post-exposure 55 Grade D Level 5
Adenosine agonists Improved survival in animals 59, 60 No studies in humans A long way from evaluation in humans NA Clonidine Improved survival in animals [61] [62] [63] No studies in humans Hypotensive effects limit evaluation in humans NA NAC Improved survival in mice 65 No studies in humans No strong physiological basis for benefit NA Enhance elimination
Haemoperfusion Trials in animals only partial response 67, 68 Retrospective study, no benefit 12 , prospective study, benefit 14 Lack of availability 73 , cost major limiting factors, could be used as an adjunct in early presenters
Grade B Level 2c
Alkalinisation Several animal trials [74] [75] [76] [77] One RCT 82 Recommendation: These preliminary observations argue that haemoperfusion may be effective early when OP tissue distribution would be incomplete (Grade B, Level 2c evidence). Routine use will however be limited by cost, availability even in Western centres and varied response depending on the V d 73 .
Alkalinisation
In early animal studies administered a 100% lethal dose of OP, the use of sodium bicarbonate resulted in 84.6% survival 74 . In a more recent study the addition of sodium bicarbonate to standard effects of atropine, obidoxime and trimedoxime 75 . in OP poisoning through several mechanisms. Postulated mechanisms include enhanced pesticide clearance through non-enzymatic or enzymatic hydrolysis 76, 77 , volume expansion and improved tissue perfusion 47,78 74 , direct effect on neuromuscular function 15, 79 as well as bicarbonate-induced release of lactate into the circulation 80, 81 .
Four uncontrolled trials and a randomised trial in humans 82 have been summarised in a systematic review 15 . In the controlled trial of 53 patients, in addition to standard treatment, 26 patients were randomised to receive sodium bicarbonate 5 mmol/kg in one hour, followed by 5 to 6 mmol/kg infusion over 23 hours 82 . The infusion was repeated daily till recovery or death. Although there was a trend towards less atropine use and shorter length of stay with bicarbonate therapy, no mortality observed. Small numbers and alternating allocation further limit conclusions.
Recommendation:
The systematic review 15 recommend alkalinisation in OP poisoning (Grade B, Level 2b evidence).
Bioremediation
Another aspect of bioscavenger therapy, under investigation, is acceleration of OP elimination by agents that metabolise OP. Historically, this dates back to the early 1970s when it was recognised that Flavobacterium species could degrade OPs. Since then, several bacterial and a few fungal species, which degrade OP with the help of structurally similar enzymes called OP hydrolase or 83 .
Recommendation: Practical applications of largescale enzymatic degradation are limited by cost and stability of the hydrolases and are still considered experimental.
CONCLUSIONS
In this review we systematically evaluated different treatment avenues that have been explored both in animal/experimental OP poisoning as well as human OP poisoning. An overview of all adjuncts and alternatives to oximes in OP poisoning is summarised in Table 2 . This review human plasma (Level C evidence), early initiation of haemoperfusion (Level B evidence) and intravenous magnesium (Level C evidence) as adjuncts to standard therapy in OP poisoning. Although these therapies are potential, it is important to assess if a particular therapy is realisable.
Evaluation of haemoperfusion as an adjunct will be limited by high costs, availability, large V d of some OPs as well as protracted OP absorption due to atropine therapy 13 . Magnesium may be an attractive option for further evaluation given lower costs particularly in the developing countries and again be limited by availability and cost. Other therapies such as adenosine receptor agonists, clonidine or NAC however cannot be deprecated in favour of more established therapies as these novel approaches may open up newer avenues for targeted therapy. However it is important to situate these therapies against the health problems in different countries as well as assess feasibility of implementing 'costly' therapies (haemoperfusion) in resource-limited nations.
The importance of OP poisoning as dimethyl or diethyl must also be considered, given the differential rates of ageing of the cholinesterase enzyme 71 and therapeutic response is the time of administration of the antidote and/or a particular treatment. pralidoxime 8 and haemoperfusion 14 were observed in patients receiving pralidoxime within 2.5 hours or haemoperfusion within six response. Thus, in patients presenting very early following OP ingestion, oximes and haemoperfusion may be considered whilst other adjuncts such as magnesium and bioscavenger therapy may be better suited for delayed presentations. Newer oximes toxicity may also need to be developed.
Whether a multi-faceted treatment approach, reducing the poison load, neutralisation of toxin, modulation of OP effects and enhancing toxin elimination (Figure 1) , will recommend itself remains to be determined. In the absence of realistic alternatives and economic constraints of implementation of potentially costly therapies, advances in the management of OP poisoning in many developing countries may be limited to public health measures such as restriction of sale of Class I OP compounds and safe pesticide storage 84 ; early recognition and prompt treatment with supportive care and the judicious use of oximes. FIGURE 1: Targeted therapy for organophosphate poisoning. Therapy in organophosphate (OP) poisoning can be targeted in several ways. Reducing absorption of the OP can be achieved by skin and gut decontamination. Neutralising the toxin can be effected by the use of nucleophilic agents such as oximes that cleave OP-acetyl cholinesterase complexes that are still not aged. Toxin neutralisation of free circulating OP may also be achieved by albumin or butyryl cholinesterase administration, both of which are present in fresh frozen plasma (FFP). The effect of OP on the central nervous system can be modulated by atropine, diazepam, clonidine or adenosine whilst cardiovascular effects could be modulated by atropine or magnesium and neuromuscular effects by magnesium. N-acetyl cysteine decreases oxidative stress related to OP-induced toxicity. Elimination of OP compounds can be enhanced by bioremediation, haemoperfusion or by alkalinisation.
